CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19

Go back to CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19
Clearview Acquisitions, Inc. (NASDAQ: CVAC) Delayed: 53.59 +0.29 (0.54%)
Previous Close $53.30    52 Week High $2.10 
Open $53.72    52 Week Low $1.50 
Day High $54.88    P/E N/A 
Day Low $52.89    EPS $-0.04 
Volume 291,860